{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:06:07Z","timestamp":1788314767293,"version":"build-2803163510"},"reference-count":26,"publisher":"Korean Association of Internal Medicine","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002642","name":"Korea University","doi-asserted-by":"publisher","award":["O2514551"],"award-info":[{"award-number":["O2514551"]}],"id":[{"id":"10.13039\/501100002642","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kjim.org"],"crossmark-restriction":true},"short-container-title":["Korean J Intern Med"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>Background\/Aims: Polatuzumab vedotin combined with bendamustine and rituximab (Pola-BR) is a treatment option for relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL), particularly as bridging therapy before chimeric antigen receptor (CAR) T-cell infusion. However, real-world data regarding its feasibility, efficacy, and safety in Korean patients are limited.Methods: We conducted a single-center retrospective study of 52 patients with R\/R DLBCL treated with Pola-BR between April 2021 and April 2024. Patients were categorized into three groups: salvage (n = 26), post-CAR T (n = 13), and bridging (n = 13). The primary endpoints were objective response rate (ORR) and complete response (CR) rate; progression-free survival (PFS), overall survival (OS), and safety were secondary endpoints.Results: The overall ORR was 51.9% (27\/52), with 36.5% (19\/52) of the patients achieving CR. The ORRs were 46.2%, 53.8%, and 61.5% in the salvage, post-CAR T, and bridging groups, respectively, with corresponding CR rates of 30.8%, 38.5%, and 46.2%. The bridging group achieved the highest response rates despite receiving a median of only one cycle, and patients with fewer prior treatment lines demonstrated superior responses. Grade 3-4 hematologic toxicities occurred in nearly all post-CAR T (100%) and salvage (92.3%) patients but were significantly lower in the bridging group (46.2%).Conclusions: Pola-BR provided meaningful disease control in patients with R\/R DLBCL. Its use as a bridging therapy before CAR T-cell infusion was associated with high response rates, favorable safety, and a successful transition to cellular therapy, underscoring its value as a practical option in this setting.<\/jats:p>","DOI":"10.3904\/kjim.2025.282","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:16:16Z","timestamp":1772781376000},"page":"296-306","update-policy":"https:\/\/doi.org\/10.3904\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma"],"prefix":"10.3904","volume":"41","author":[{"given":"Changgon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duck","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-4401","authenticated-orcid":true,"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2270","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2023.0388"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00172"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116596"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800"},{"key":"ref7","volume-title":"","year":"2017"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000798"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-05052-x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005953"},{"key":"ref11","first-page":"336","volume-title":"Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas","author":"Dimou","year":"2021"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004155"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13784"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05273-8"},{"key":"ref15","first-page":"586","volume-title":"","author":"Morita","year":"2023"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-025-00059-5"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000102"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.1618"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001900"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000151"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303959"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3892\/ol_00000119"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04711-9"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2024.100467"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3155"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2174\/157339406777934717"}],"container-title":["The Korean Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/kjim.org\/upload\/kjim-2025-282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2025.282","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/kjim.org\/upload\/kjim-2025-282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:57:13Z","timestamp":1774933033000},"score":1,"resource":{"primary":{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2025.282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.3904\/kjim.2025.282","relation":{},"ISSN":["1226-3303","2005-6648"],"issn-type":[{"value":"1226-3303","type":"print"},{"value":"2005-6648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"2025-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-01","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}